# MajesTEC-1 (NCT03145181)

> Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03145181
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Hematological Malignancies
- Interventions: Teclistamab (IV); Teclistamab(SC)
- Enrollment: 302
- Primary outcome: Dose Limiting Toxicity (DLT)
- Primary outcome: Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 109
- X threads: 70
- Podcasts: 58
- Bluesky threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=majestec-1-nct03145181

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03145181", "email": "<work email>"}; the inbox owner confirms by the emailed link.